Sands Capital Life Sciences Pulse Fund II, L.P.
CIK: 0001875620
Transaction Breakdown
Open Market Buys (P)1 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
IKT
Inhibikase Therapeutics, Inc.
10% Owner
Discretionary Trading P&L
Holdings
About Sands Capital Life Sciences Pulse Fund II, L.P.
Sands Capital Life Sciences Pulse Fund II, L.P. (SEC CIK 0001875620) files insider reports with the SEC as 10% Owner of Inhibikase Therapeutics, Inc. (IKT).
Signal8 holds 3 ownership filings by Sands Capital Life Sciences Pulse Fund II, L.P. (2 Form 3, 1 Form 4), filed between Oct 25, 2024 and Nov 24, 2025. Those filings report 1 transaction, the latest on Nov 21, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Sands Capital Life Sciences Pulse Fund II, L.P.'s filings is in ARLINGTON, VA.
Recent filings by Sands Capital Life Sciences Pulse Fund II, L.P.
- Nov 21, 2025: Open-market purchase of IKT shares (Form 4, code P).
Other insiders filing for Inhibikase Therapeutics, Inc. (IKT)
- Wasserman Scott M., Director
- RA CAPITAL MANAGEMENT, L.P., 10% Owner
- Aurentz Vincent, Director
- Cabell Christopher, President & Head of R&D
- Munshi Amit, Director
- Iwicki Mark T, Chief Executive Officer